Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Agenus stock | 4.2

Own Agenus stock in just a few minutes.


Fact checked

Agenus Inc is a biotechnology business based in the US. Agenus shares (AGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Agenus employs 328 staff and has a trailing 12-month revenue of around USD$96.5 million.

How to buy shares in Agenus

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Agenus. Find the stock by name or ticker symbol: AGEN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Agenus reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.2, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Agenus, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Agenus. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Agenus's share price?

Since the stock market crash in March caused by coronavirus, Agenus's share price has had significant positive movement.

Its last market close was USD$4.2, which is 16.19% up on its pre-crash value of USD$3.52 and 130.77% up on the lowest point reached during the March crash when the shares fell as low as USD$1.82.

If you had bought USD$1,000 worth of Agenus shares at the start of February 2020, those shares would have been worth USD$540.76 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,141.31.

Agenus share price

Use our graph to track the performance of AGEN stocks over time.

Agenus shares at a glance

Information last updated 2020-10-14.
Latest market close USD$4.2
52-week range USD$1.82 - USD$5.63
50-day moving average USD$4.3686
200-day moving average USD$3.5436
Wall St. target price USD$8
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.906

Buy Agenus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Agenus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Agenus price performance over time

Historical closes compared with the close of $4.2 from 2020-10-19

1 week (2020-11-20) 15.07%
1 month (2020-10-30) 13.82%
3 months (2020-08-28) -1.87%
6 months (2020-05-29) 12.60%
1 year (2019-11-29) 0.24%
2 years (2018-11-29) 82.61%
3 years (2017-11-29) 8.81%
5 years (2015-11-27) -18.13%

Agenus financials

Revenue TTM USD$96.5 million
Gross profit TTM USD$-18,291,000
Return on assets TTM -35.24%
Return on equity TTM 0%
Profit margin -173.74%
Book value $-1.145
Market capitalisation USD$757.6 million

TTM: trailing 12 months

Shorting Agenus shares

There are currently 23.1 million Agenus shares held short by investors – that's known as Agenus's "short interest". This figure is 0.4% up from 23.1 million last month.

There are a few different ways that this level of interest in shorting Agenus shares can be evaluated.

Agenus's "short interest ratio" (SIR)

Agenus's "short interest ratio" (SIR) is the quantity of Agenus shares currently shorted divided by the average quantity of Agenus shares traded daily (recently around 3.9 million). Agenus's SIR currently stands at 5.95. In other words for every 100,000 Agenus shares traded daily on the market, roughly 5950 shares are currently held short.

However Agenus's short interest can also be evaluated against the total number of Agenus shares, or, against the total number of tradable Agenus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agenus's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Agenus shares in existence, roughly 130 shares are currently held short) or 0.1412% of the tradable shares (for every 100,000 tradable Agenus shares, roughly 141 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Agenus.

Find out more about how you can short Agenus stock.

Agenus share dividends

We're not expecting Agenus to pay a dividend over the next 12 months.

Have Agenus's shares ever split?

Agenus's shares were split on a 1:6 basis on 3 October 2011. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Agenus shares which in turn could have impacted Agenus's share price.

Agenus share price volatility

Over the last 12 months, Agenus's shares have ranged in value from as little as $1.82 up to $5.63. A popular way to gauge a stock's volatility is its "beta".

AGEN.US volatility(beta: 1.96)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.9592. This would suggest that Agenus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Agenus overview

Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site